Moscow, Oct. 18 (Petra) -- The National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation announced on Sunday the successful completion of phases I and II of clinical trials for a liver cancer treatment named "Hepatorin-mRNC," targeting primary tumors and liver metastases.

Chief Oncologist of the Russian Ministry of Health, Andrey Kaprin, stated that the drug utilizes albumin microspheres loaded with a radioactive isotope, enabling targeted radiation therapy delivered directly to the tumor. He confirmed that both Phase I and Phase II clinical studies have been completed.

//Petra// AF